Trial Profile
A Two-stage Phase II Study of Autologous TriMix-DC Therapeutic Vaccine in Combination With Ipilimumab in Patients With Previously Treated Unresectable Stage III or IV Melanoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 30 Mar 2021
Price :
$35
*
At a glance
- Drugs Ipilimumab (Primary) ; TriMix DC (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- Acronyms TRIMIXIPI
- 29 Feb 2016 Results published in the Journal of Clinical Oncology
- 16 Aug 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 21 Mar 2012 Planned End Date added to 1 Aug 2012 as reported by ClinicalTrials.gov.